Methylenetetrahydrofolate reductase polymorphisms in myeloid leukemia patients from Northeastern Brazil
Barbosa, Cynara Gomes; Souza, Claudio Lima; Moura Neto, José Pereira de; Arruda, Maria da Glória Bomfim; Barreto, José Henrique; Reis, Mitermayer Galvão; Goncalves, Marilda Souza.
Genet. mol. biol
; 31(1): 29-32, 2008. tab
Artigo em Inglês | LILACS | ID: lil-476145
A possible connection between circulating 25-hydroxy-vitamin D and molecular response in chronic myeloid leukemia.
Phase 2 study of nilotinib in pediatric patients with Philadelphia chromosome-positive chronic myeloid leukemia.
How I treat chronic myeloid leukemia in children and adolescents.
[Chronic myeloid leukemia - update 2020].
Epigenetic dysregulation in chronic myeloid leukaemia: A myriad of mechanisms and therapeutic options.
[Co-occurrence of t(8;21)(q22;q22) and t(9;22)(q34;q11) in a case with chronic myelogenous leukemia].
[Successful treatment with ponatinib in combination with hyper-CVAD for chronic myeloid leukemia in the lymphoid blastic phase].
[Adverse events of ABL tyrosine kinase inhibitors in chronic myeloid leukemia therapy].
Circular RNA circHIPK3 serves as a prognostic marker to promote chronic myeloid leukemia progression.
Exploring Patient Decision Making Regarding Discontinuation of Tyrosine Kinase Inhibitors for Chronic Myeloid Leukemia.